Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

Shares of clinical-stage gene-therapy company, Adverum Biotechnologies, Inc. ADVM, have gained after the FDA lifted the clinical hold on the second cohort of phase I trial on lead candidate, ADVM-022.